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ABSTRACT—Background: The nitric oxide system could playan important role in the pathophysiology related to necrotizing soft
tissue infection (NSTI). Accordingly, we investigated the association between plasma nitrite level at admission and the presence of
septic shock in patients with NSTI. We also evaluated the association between nitrite, asymmetric dimethylarginine (ADMA), L-
arginine, L-arginine/ADMA ratio, and outcome. Methods: We analyzed plasma from 141 NSTI patients taken upon hospital
admission. The severity of NSTI was assessed by the presence of septic shock, Simplified Acute Physiology Score (SAPS) II,
Sepsis-Related Organ Failure Assessment (SOFA) score, use of renal replacement therapy (RRT), amputation, and 28-day
mortality. Results: No difference in nitrite levels was found between patients with and without septic shock (median 0.82mmol/L
[interquartile range (IQR) 0.41–1.21] vs. 0.87mmol/L (0.62–1.24), P¼0.25). ADMA level was higher in patients in need of RRT
(0.64mmol/L (IQR 0.47–0.90) vs. (0.52mmol/L (0.34–0.70), P¼0.028), and ADMA levels correlated positively with SAPS II
(rho¼0.32, P¼0.0002) and SOFA scores (rho¼0.22, P¼0.01). In a logistic regression analysis, an L-arginine/ADMA ratio below
101.59was independentlyassociatedwith 28-daymortality, odds ratio 6.03 (95%confidence interval, 1.41–25.84),P¼0.016.None
of the other analyses indicateddifferences in theNOsystembasedon differences in disease severity.Conclusions: In patientswith
NSTI, we found no difference in baseline nitrite levels according to septic shock. High baseline ADMA level was associated with the
useofRRTandpatientswitha lowbaseline L-arginine/ADMAratiowereat higher riskof dyingwithin28daysafter hospital admission.
KEYWORDS—Bacterial infection, biomarker, endothelium, necrotizing fasciitis, nitric oxide, sepsis, survival
INTRODUCTION
Necrotizing soft tissue infections (NSTIs) represent a spec-
trum of bacterial infections causing necrotic lesions in any layer
of the soft tissue compartments. Each year, approximately
1,000 people are diagnosed with the disease in the United
States (1, 2).
Nitric oxide (NO) is involved in a wide variety of regulatory
mechanisms and exerts its physiological role through the
cardiovascular, immune, and nervous systems (3, 4). NO is
derived from the vascular wall and it is thought to contribute to
hypotension in patients with sepsis, but it may also improve
organ perfusion by microcirculatory vasodilation (5, 6). This
could be of clinical importance as NSTI is often accompanied
by septic shock and organ failure (7). However, the mechanisms
linking NSTI to vascular dysfunction remain to be investigated.
Interestingly, NO is also involved in the host–pathogen inter-
actions through its function as a signaling molecule, antimi-
crobial agent, and downstream effector of innate immunity (8–
10), thus potentially playing a role during NSTI.
NO is formed in the vascular endothelium by NO synthase
(NOS) from L-arginine and oxygen. Once produced, NO
(half-life <2 ms) is rapidly oxidized to nitrite (NO2
) and
nitrate (NO3
) in blood. Together, these two metabolites are
widely used as an indirect measure of NO plasma levels (11–
13). There is a growing interest in nitrite as it reflects
constitutive NO availability (14) and provides a more reliable
measure of endothelial NOS (eNOS) activity compared with
nitrate (15, 16), whereas inducible NOS (iNOS) is thought to
release an order of magnitude more NO in response to tissue
damage and infection (17, 18). Therefore, nitrite assessment
may aid in the early detection of endothelial dysfunction, but
its prognostic role in critically ill patients has been sparsely
evaluated due to the lack of sufficiently sensitive analytical
methods (19, 20).
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NOS activity is inhibited endogenously by asymmetric
dimethylarginine (ADMA). An imbalance of NO (nitrite/
nitrate), L-arginine, and ADMA is thought to be involved in
endothelial and cardiac dysfunction (21). In line with this, high
ADMA levels have been associated with increased mortality in
patients with sepsis (22–24) and as an independent risk factor
of intensive care unit (ICU) mortality (25), but data are con-
flicting (26). As ADMA competes with L-arginine for the
binding to NOS, the L-arginine/ADMA ratio has been sug-
gested as a better indicator to NOS substrate availability than L-
arginine alone (27). NO, ADMA, and L-arginine are potential
therapeutic targets and may be used in the identification of
relevant subgroups of patients at high risk of poor outcome. To
our knowledge, no studies have investigated the levels of these
vasoactive biomarkers in patients with NSTI, despite the
pathophysiological differences compared with other patients
with sepsis. In addition, the treatment of NSTI often relies on
knowledge from sepsis patients with pneumonia or other
frequent sites of infection even though the immunological
processes likely differ because of the extensive necrosis. More-
over, the diagnosis of NSTI is clinical which makes it interest-
ing to investigate whether these biomarkers are able to predict
patient outcome.
Accordingly, we evaluated the association between the
level of NO system biomarkers in plasma and disease
severity and outcome in patients with NSTI. The primary
analysis focused on the association between nitrite level
upon hospital admission (baseline) and septic shock. In
the secondary analyses, we focused on the association
between nitrite, L-arginine, ADMA, and L-arginine/ADMA
ratio and disease severity as well as outcome, defined as use
of renal replacement therapy (RRT), rates of amputation, and
28-day mortality.
MATERIALS AND METHODS
Study design and population
In Denmark, the treatment of NSTI has been centralized at Rigshospitalet,
University ofCopenhagen,where this prospective, observational cohort studywas
conducted between February 2013 and April 2015. The study protocol has been
published (28) and is available online (ClinicalTrials.gov: NCT02180906).
We included patients diagnosed with NSTI, based on surgical findings of
necrosis. Inclusion criteria included admission to the ICU or surgery for NSTI at
Rigshospitalet and a minimum age of 18 years. Patients were excluded if the
diagnosis could not be confirmed during surgery.
Data collection
Data were obtained from patient medical records and entered into an online
database that was regularly validated. The following data were retrieved from
the database: demographics (age, sex), comorbidities (diabetes, liver cirrhosis,
chronic kidney disease, cardiovascular disease, chronic obstructive pulmonary
disease, peripheral vascular disease, immune deficiency, malignancy, rheuma-
toid disease), biochemistry and physiological values, and disease severity
scores (Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC), Simpli-
fied Acute Physiology Score (SAPS) II, Sepsis-Related Organ Failure Assess-
ment (SOFA) score). Data on vital status (date of death or emigration) were
retrieved from the Danish Civil Registration System. The presence of septic
shock was defined according to Bone et al. (29) with at least two systemic
inflammatory response syndrome (SIRS) criteria, suspected/verified focus of
infection and vasopressor infusion.
Arterial blood was obtained in EDTA tubes upon hospital admission and
immediately put on ice. After centrifugation, plasma was collected in 1mL
aliquots and stored at 808C until processing. In 67% (n¼ 94) of the cases,
baseline blood samples were collected after the primary operation of NSTI.
Chemiluminescent assay
We quantified baseline plasma NO level indirectly through the measurement
of nitrite using the ozone-chemiluminescence technology (Sievers Nitric Oxide
Analyzer system, NOA 280i, GE Analytical Instruments, Boulder, Colo) as
previously described (30). In brief, we thawed the plasma just before NO
determination under the protection from light. We injected 300mL plasma
sample into the purge vessel of the NO analyzer containing glacial acetic acid
and an iodide solution (NaI and KI), which converts nitrite to NO. Samples were
tested in duplicates using a standard curve constructed with distilled water as
blanks and sodium nitrite solutions of known concentrations (10 nM, 50 nM,
100 nM, 1mM, 5mM, 10mM, 50mM, and 100mM), which yielded a linear
relationship. The lower detection limit in the samples was 15 nM due to the
nitrite content in the empty EDTA sampling tubes.
Enzyme-linked immunosorbent assay
We measured baseline plasma ADMA and L-arginine using a competitive
enzyme-linked immunosorbent assay (ELISA) (EA207/92; DLD Diagnostica
GmbH, Hamburg, Germany) according to the manufacturer’s instructions.
Samples were tested in duplicate against a standard pool with known concen-
tration. The standard range of ADMA was 0.2 to 3.0mmol/L (normal values
0.40–0.75mmol/L) with an intra-assay variation of 6% and interassay of 10%.
The standard range of L-arginine was 5 to 300mmol/L (normal values 20–
80mmol/L) with an intra-assay variation of 4% and interassay variation of 10%.
Statistical analysis
Categorical data are presented as numbers with percentage (%) and
compared using the chi-square test. Continuous data are presented as
medians with interquartile range (IQR). We used the unpaired t test for
the primary analysis to quantify potential differences between the groups
and elaborate on a potential risk of overlooking a clinical relevant differ-
ence. As data were not normally distributed, we used the Mann–Whitney U
test for significance testing of differences between groups (28). The
association between 28-day mortality and biomarker levels are illustrated
with Kaplan–Meier plots and tested using a logistic regression analysis and
expressed with odds ratio (OR) and 95% confidence interval (CI). In the
prediction of 28-day mortality, we analyzed both median values and optimal
cutoff (maximum sum of sensitivity and specificity) (28). In the multivariate
analysis, we adjusted for age, sex, comorbidities, and SAPS II. Patients with
missing data on covariates were excluded in the multivariate analyses. No
data were missing on the outcome variable, thus no multiple imputations
were performed. We analyzed receiver operating characteristic (ROC)
curves for 28-day mortality and Spearman rank test for correlation between
biomarker level and disease severity.
P< 0.05 was considered to be statistically significant. Analyses were
performed using GraphPad Prism 6.0 software (Graphpad Inc., Calif) and
SPSS 22.0 software (SPSS Inc., Ill).
Initially, we planned to include 110 patients based on a sample size
calculation using total levels of nitrate and nitrite (28). As we aimed to measure
only nitrite levels in the samples, this estimate is subject to great uncertainty,
especially as no studies have investigated nitrite levels exclusively in infected
patients using chemiluminescent. We therefore decided to analyze all samples
obtained from patients with NSTI, who were included during the study period,
as previously described (7). Baseline characteristics of the majority of the study
cohort (n¼ 135) have been previously described in two studies elaborating on
pattern recognition molecules (7, 31).
Ethics
The regional ethics committee (H-2-2014-071) and the Danish Data Pro-
tection Agency (30-1282) approved the study. All patients or their next of kin
gave oral and written informed consent.
RESULTS
We enrolled 171 patients with suspected NSTI between
February 2013 and April 2015. Of those, 30 patients did not
fulfill the inclusion criteria or fulfilled the exclusion criterion.
Thus, we analyzed 141 baseline samples from patients with
NSTI. The patients had a median age of 62 years (53–69) and
60% were men. The majority of patients presented with septic
shock (72%) and 28-day mortality was 17% (n¼ 24 (95% CI,
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12%–24%)). Themedian SAPS IIwas 45 (35–54) and could not
be calculated in five patients due to missing data.
Disease severity
Patients with NSTI and septic shock had a mean baseline
nitrite level of 0.88mmol/L compared with 1.00mmol/L in
those without septic shock (mean difference 0.12mmol/L (95%
CI, –0.10 to 0.34), P¼ 0.83) and we found no significant
difference between the groups using the Mann–Whitney U
test (median 0.82mmol/L, IQR 0.41–1.21 vs. 0.87mmol/L,
IQR 0.62–1.24, P¼ 0.25) (Fig. 1). Only baseline ADMA level
was significantly higher in patients in need of RRT within the
first 7 days of admission (Figs. 1 and 2). This was in line with
the correlation analyses showing that ADMA correlated sig-
nificantly with the SAPS II and the SOFA score (Table 1). In
addition, nitrite, ADMA, and L-arginine/ADMA ratio corre-
lated with creatinine levels.
Mortality
Survival according to median biomarker levels and 28-day
mortality is illustrated in Figure 3 and the diagnostic accuracy is
shown in Table 2. Only a L-arginine/ADMA ratio below the
median correlated significantly with the mortality, but it was
not an independent predictor (Table 3). However, when the
optimal cutoff was used (maximum sum of sensitivity and
specificity) instead of the median, the L-arginine/ADMA ratio
independently predicted the 28-day mortality (Table 4).
DISCUSSION
We found no difference in admission (baseline) plasma
nitrite level according to septic shock in patients who had
NSTI. In contrast, baseline ADMA level was associated with
the use of RRTand it correlated with the SAPS II and the SOFA
score. In line with this, patients with an L-arginine/ADMA ratio
below 101.59 (optimal cutoff) upon hospital admission had 5
times the odds of dying within the first 28 days.
A main strength of this study is the full follow-up of the
patients due to the individually assigned person number that is
coupled to the national health registries. Furthermore, treatment
ofNSTI has been centralized at a national level at Rigshospitalet,
University of Copenhagen, providing us with the opportunity to
investigate the disease in a large but well-defined geographical
area, increasing the external validity of the study.
A number of limitations need to be taken into consider-
ation. First, the study might be subject to bias because of the
inability to control for unknown confounders. We decided a
priori to adjust for potential confounders (age, sex, comor-
bidities, and SAPS II) that most likely affect disease severity
and mortality. It has previously been shown that kidney
function has an impact on the nitrite, L-arginine, and ADMA
levels in plasma (32), and this is confirmed in this study
because there was a significant correlation between the
biomarker levels and the creatinine levels. An adjustment
for this was done as urine output and blood urea nitrogen
FIG. 1. Plasma levels of nitrite, L-arginine, ADMA, and L-arginine/ADMA ratio on admission according to septic shock in patients with necrotizing
soft tissue infection.ADMA indicates asymmetric dimethylarginine.Medianwith interquartile range is illustrated. Comparisonswere performed using theMann–
Whitney U test.
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levels are included in the SAPS II. Hemodilution may also be
an important factor to consider. One would expect patients
with severe illness (i.e., septic shock) to receive more fluids,
thus influencing biomarker levels. Unfortunately, we do not
have data on the amount on fluid resuscitation before the
blood samples were obtained. However, in a previous study
constituting the same cohort as this, we found no difference
in hemoglobin levels in patients with and without septic
shock (7), indicating that a potential diluting factor may not
affect data significantly.
Second, five patients (3.5%) had missing SAPS II data and
were not included in the multivariate analyses. No major
changes were seen in OR when SAPS II was included in the
final step of adjustment, thus making it unlikely for the
missing values of the five patients to have a major impact.
Moreover, we conducted multiple analyses, and the analyses
regarding L-arginine, ADMA, L-arginine/ADMA ratio, and
outcome were secondary in nature, thus increasing the risk of
chance findings. Therefore, the diagnostic accuracy of the
biomarkers should be tested in another cohort. It is also
relevant to investigate these biomarkers in future cohorts
defined by the Sepsis-3 Septic Shock definitions (33). In this
study, most of the patients in the septic shock group (hypo-
tension and receiving vasopressors) will probably also meet
the Sepsis-3 definition as they also exhibited a lactate
increase. However, the precise impact of the Sepsis-3
TABLE 1. Spearman rank correlation between disease severity scores and baseline biomarker levels in patients with necrotizing soft
tissue infection
LRINEC SAPS II SOFA score* Creatinine**
Rho P Rho P Rho P Rho P
Nitrite 0.11 0.25 0.13 0.15 0.30 0.001 0.23 0.009
L-Arginine 0.13 0.17 0.09 0.33 0.02 0.87 0.12 0.17
ADMA 0.05 0.59 0.32 0.0002 0.22 0.01 0.17 0.048
L-Arginine/ADMA ratio 0.07 0.43 0.14 0.10 0.12 0.18 0.22 0.01
*SOFA score day 1.
**Highest value measured during the first 24 h of admission.
ADMA indicates asymmetric dimethylarginine; LRINEC, Laboratory Risk Indicator For Necrotizing Fasciitis; SAPS II, Simplified Acute Physiology Score
II; SOFA, Sepsis-Related Organ Failure Assessment.
FIG. 2. Plasma levels of nitrite, L-arginine, ADMA, and L-arginine/ADMA ratio on admission according to amputation and RRTwithin the first 7 days
in patients with necrotizing soft tissue infection. ADMA indicates asymmetric dimethylarginine; RRT, renal replacement therapy. Median with interquartile
range is illustrated. Comparisons were performed using the Mann–Whitney U test.
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FIG. 3. Kaplan–Meier curves with related 95%CIs of 28-daymortality in patients with necrotizing soft tissue infection according to levels above or
below median biomarker levels. ADMA indicates asymmetric dimethylarginine.
TABLE 2. Diagnostic accuracy of high baseline nitrite and ADMA levels and low baseline L-arginine level and L-arginine/ADMA ratio in
predicting 28-day mortality in patients with necrotizing soft tissue infection
Nitrite L-Arginine ADMA L-Arginine/ADMA
Sensitivity 0.50 (0.31–0.69) 0.58 (0.39–0.76) 0.63 (0.42–0.80) 0.71 (0.51–0.86)
Specificity 0.50 (0.46–0.54) 0.52 (0.48–0.56) 0.53 (0.48–0.56) 0.54 (0.50–0.58)
PPV 0.18 (0.11–0.25) 0.20 (0.13–0.27) 0.22 (0.15–0.28) 0.25 (0.18–0.30)
NPV 0.82 (0.75–0.89) 0.86 (0.79–0.92) 0.87 (0.80–0.93) 0.90 (0.83–0.95)
Area under ROC curve 0.48 (0.34–0.62) 0.52 (0.38–0.65) 0.63 (0.51–0.75) 0.63 (0.53–0.73)
ADMA indicates asymmetric dimethylarginine; NPV, negative predictive value; PPV, positive predictive value. Data are presented as fractions (95% CI).
The prevalence of 28-day mortality was 17%. High and low baseline levels were defined by the median.
TABLE 3. Univariate andmultivariate logistic regression analyses of mortality up to day 28 (time of censoring) in patients with necrotizing soft
tissue infection based on high versus low concentrations of the biomarkers according to median values
Unadjusted
Adjusted for age, sex,
chronic disease
Adjusted for sex,
chronic disease, SAPS II*
OR 95% CI P OR 95% CI P OR 95% CI P
Nitrite
Low (0.82mmol/L) 1 1 1
High (>0.82mmol/L) 1.00 0.41–2.42 1.00 0.84 0.34–2.11 0.71 1.3 0.41–4.11 0.66
L-Arginine
High (>50.28mmol/L) 1 1 1
Low (50.28mmol/L) 1.50 0.62–3.66 0.37 1.44 0.58–2.56 0.43 2.82 0.83–9.66 0.10
ADMA
Low (0.54mmol/L) 1 1 1
High (>0.54mmol/L) 1.85 0.75–4.58 0.18 1.84 0.73–4.63 0.20 1.2 0.38–3.86 0.76
L-Arginine/ADMA ratio
High (>89.38) 1 1 1
Low (89.38) 2.90 1.12–7.52 0.029 2.59 0.98–6.85 0.06 3.07 0.90–10.48 0.07
*Five patients were not included in the analysis due to missing data of SAPS II (one of whom died the first day of admission). When the missing variables
were replaced with the minimal value andmaximum value, the median SAPS II was 27 (18–44) and 37 (30–54), respectively, compared with 45 (35–54)
for the entire cohort. Age is included in SAPS II.
ADMA indicates asymmetric dimethylarginine; CI, confidence interval; OR, odds ratio; SAPS II, Simplified Acute Physiology Score II.
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definition needs to be investigated in future studies. Impor-
tantly, we used the same criteria as previous studies investi-
gating vasoactive biomarkers, which allow us to make
relevant comparisons of the results and conclusions.
Third, the results from the logistic regression analyses had
rather wide 95% CIs, thus complicating the interpretation.
However, a low L-arginine/ADMA ratio upon hospital admis-
sion was associated with increased mortality and OR for
death at Day 28 was approximately 5 as compared with
patients with a high L-arginine/ADMA ratio. The L-arginine/
ADMA ratio has been suggested as a superior indicator of
NO dysfunction as the production of NO might be affected
by abnormal levels of both L-arginine and ADMA (21, 27).
There are conflicting data on the association between L-
arginine, ADMA, and mortality in patients with sepsis and
septic shock (21, 22, 24, 26, 34–36), but there seems to be a
relatively consistent association between low L-arginine/
ADMA ratio and mortality in infected patients (21, 22,
34, 37). However, the studies are limited by a small number
of patients and the use of different time points of mortality
assessment and different cutoff levels. A recent study inves-
tigating 267 patients with severe sepsis or septic shock found
a significant association between high baseline ADMA levels
and 90-day mortality, but no association between L-arginine/
ADMA ratio and mortality (38). The results of that study
may not be directly comparable to those of our study as the
most frequent sources of infection in the former were the
lungs and abdomen. In our study, all patients were severely
infected in the soft tissues and/or muscles with associated
tissue necrosis. It may be that the pathophysiology of these
infections differs and that the response pattern from the NO
system and the associated biomarkers varies.
In line with this, we are not able to establish a mechanistic
explanation for our findings. However, the association
between L-arginine/ADMA ratio and mortality could be
attributed to the NO system. Endothelial cells regulate blood
flow in microvessels by producing NO. Interestingly, the
microcirculation is impaired in patients with septic shock
and this is associated with higher mortality (39, 40). More-
over, NO production is stimulated by TNF-a and IL-1, and the
level of both cytokines is increased in this group of patients
and also associated with disease severity and mortality (41). It
would have been interesting to investigate the NOS expression
in these patients as the pronounced inflammation may be a
significant inducer of inducible NOS, contributing to circu-
lating NO metabolites (42).
We used nitrite level as a surrogate measure of NO produc-
tion because the half-life of NO in blood is short making it
difficult to measure (43, 44). In plasma, NO reacts with oxygen
species to form nitrate and nitrite. Nitrite is the major oxidation
product of NO in the absence of oxyhemoglobin or superoxide
anion and may be a more reliable measure of eNOS activity
than nitrate (15, 16). NO synthesis in vascular endothelial cells
is of special interest as it reflects the microcirculation, thus
making nitrite measurements relevant to our patients. Nitrate,
on the contrary, is influenced by numerous factors, such as diet,
the intestinal bacterial flora, and renal function. In addition,
there are high concentrations of nitrate in plasma that makes it
difficult to detect acute changes in accordance to eNOS (45).
We are aware that the accuracy of the measurements are
limited, but the purpose with this study was to determine
whether clinically relevant differences exist between subgroups
of patients with NSTI according to disease severity and mor-
tality. Importantly, there seem to be an association between low
substrate availability (L-arginine), high levels of NO inhibitor
(ADMA), and mortality.
We speculate that this imbalance in the NO system contrib-
utes to an unfavorable impairment of the microcirculation of
patients with NSTI causing organ failure and increased mor-
tality. Further studies are needed to elucidate the precise
mechanisms, but if endothelial dysfunction turns out to play
a crucial role for clinical outcome, L-arginine and ADMAwill
be interesting biomarkers as well as the modulation of the NO
pathway for this group of critically ill patients.
TABLE 4. Univariate andmultivariate logistic regression analyses of mortality up to day 28 (time of censoring) in patients with necrotizing soft
tissue infection based on high versus low concentrations of the biomarkers according to the optimal cutoff
Unadjusted
Adjusted for age, sex,
chronic disease
Adjusted for sex,
chronic disease, SAPS II*
OR 95% CI P OR 95% CI P OR 95% CI P
Nitrite
Low (1.49mmol/L) 1 1 1
High (>1.49mmol/L) 2.20 0.62–7.85 0.22 1.87 0.50–6.93 0.35 4.60 0.92–23.03 0.06
L-Arginine
High (>71.98mmol/L) 1 1 1
Low (71.98mmol/L) 0.59 0.23–1.54 0.28 0.56 0.21–1.48 0.24 0.61 0.18–2.06 0.43
ADMA
Low (0.40mmol/L) 1 1 1
High (>0.40mmol/L) 11.5 1.50–88.41 0.02 10.23 1.32–79.38 0.03 13.17 0.91–191 0.06
L-Arginine/ADMA ratio
High (>101.59) 1 1 1
Low (101.59) 5.76 1.85–17.90 0.003 5.02 1.59–15.91 0.006 6.03 1.41–25.84 0.016
*Five patients were not included in the analysis due to missing data of SAPS II (one of whom died the first day of admission). When the missing variables
were replaced with the minimal value andmaximum value, themedian SAPS II was 27 (18–44) and 37 (30–54), respectively. Age is included in SAPS II.
Optimal cutoff was found by the maximum sum of sensitivity and specificity.
ADMA indicates asymmetric dimethylarginine; CI, confidence interval; OR, odds ratio; SAPS II, Simplified Acute Physiology Score II.
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CONCLUSIONS
In patients with NSTI, we found no difference in baseline
nitrite level according to presence of septic shock. High
baseline ADMA level was associated with use of RRT, and
patients with a low baseline L-arginine/ADMA ratio were in
higher risk of dying within first 28 days of hospital admission.
Our findings support the hypothesis that the NO system plays
an important role in the pathophysiology related to NSTI.
However, this needs to be validated in other cohorts.
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